The Red Section

The Cochrane Review Conclusion for Hepatitis C DAA Therapies is Wrong

  • The American Journal of Gastroenterology volume 113, pages 24 (2018)
  • doi:10.1038/ajg.2017.420
  • Download Citation
  • Subscribe to The American Journal of Gastroenterology for full access:



Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.


  1. 1.

    . Helicobacter pylori infection in the pathogenesis of duodenal ulcer and gastric cancer: a model. Gastroenterology 1997;113:1983–1991.

  2. 2.

    , , et al. Trends in hospitalizations for peptic ulcer disease, United States, 1998–2005. Emerg Infect Dis 2010;16:1410–1418.

  3. 3.

    . Review article: the epidemiology and prevention of gastric cancer. Aliment Pharmacol Therap 2014;40:250–260.

  4. 4.

    , , et al. Colonoscopy reduces colorectal cancer incidence and mortality in patients with non-malignant findings: a meta-analysis. Am. J. Gastroenterol. 2016;111:355–365.

  5. 5.

    , , et al. Interferon for interferon naive patients with chronic hepatitis C. Cochrane Database Syst Rev 2002:(2): CD002234.

  6. 6.

    , , et al. Global epidemiology of hepatitis C virus infection: new estimates of age‐specific antibody to HCV seroprevalence. Hepatology 2013;57:1333–1342.

  7. 7.

    , , . Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the US. Hepatology 2014;59:2188–2195.

  8. 8.

    , , et al. Liver transplantation: East versus West. J. Clin. Exp. Hepatol 2013;3:243–253.

  9. 9.

    , . Peginterferon and ribavirin for chronic hepatitis C [see comment]. N Engl J Med 2006;355:2444–2451.

  10. 10.

    , , et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014;384:1756–1765.

  11. 11.

    , , et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368:1867–1877.

  12. 12.

    , , et al(eds). A Randomized, Controlled, Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir or Sofosbuvir/Velpatasvir for 12 Weeks in Direct Acting Antiviral-Experienced Patients with Genotype 1-6 HCV Infection: The POLARIS-4 Study. HepatologyWiley-Blackwell: New Jersey, 2016.

  13. 13.

    , , et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis. J Hepatol 2017;67:263–271.

  14. 14.

    , , et al. Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection. Gastroenterology 2016;150:419–429.

  15. 15.

    , , et al. P0775: final evaluation of 955 HCV patients treated with 12 week regimens containing sofosbuvir+/− simeprevir in the trio network: academic and community treatment of a real-world, heterogeneous population. J Hepatol 2015;62:S621.

  16. 16.

    , , et al. Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients. Hepatology 2010;51:1137–1143.

  17. 17.

    , , et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584–2593.

  18. 18.

    , , et al. Is there sufficient evidence to recommend antiviral therapy in hepatitis C? J Hepatol 2014;60:191–196.

  19. 19.

    , , et al. Association between severe portal hypertension and risk of liver decompensation in patients with hepatitis C, regardless of response to antiviral therapy. Clin Gastroenterol Hepatol 2015131846–53.e1.

  20. 20.

    , . Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis 2011;52:889–900.

  21. 21.

    , , et al. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol 2005;42:632–638.

  22. 22.

    , , et al. Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. J Hepatol 2013;59:169–177.

  23. 23.

    , , et al. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. Hepatology 2017;65:804–812.

  24. 24.

    , , et al. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus–infected patients awaiting liver transplantation. Liver Transplant 2002;8:350–355.

  25. 25.

    , , et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study. J Hepatol 2016;65:524–531.

  26. 26.

    , , et al. Treatment of hepatitis C virus–associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology 2016;63:408–417.

  27. 27.

    . The impact of antiviral therapy for hepatitis C on the quality of life: a perspective. Liver Int 2017;37:7–12.

  28. 28.

    , , et al. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev 2017;6:Cd012143.

  29. 29.

    , , et al. Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C. Cochrane Database Syst Rev 2014:(2): CD005441.

  30. 30.

    , , et al. Medicinal herbs for hepatitis C virus infection. Cochrane Database Syst Rev 2001:(4): CD003183.

  31. 31.

    , , et al. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology 2011;140:1990–1999.

  32. 32.

    , , et al. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 2004;25:472–492.

  33. 33.

    , , et al. Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. Cochrane Database Syst Rev 2013:(1): CD003617.

  34. 34.

    , , et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463–472.

  35. 35.

    , , et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015;149:649–659.

  36. 36.

    , , et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis 2016;16:685–697.

  37. 37.

    , , et al. Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or posttransplant recurrence: phase 3 ALLY-1 study. J Hepatol 2015;62 (Suppl 2): S261.

Download references

Author information


  1. Division of Gastroenterology/Hepatology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California, USA

    • Paul Y Kwo
  2. Bon Secours Liver Institute of Virginia, Bon Secours Medical Group, Newport News and Richmond, Virginia, USA

    • Mitchell L Shiffman
  3. Division of Hepatology and Center for Liver Diseases, North Shore Long Island Jewish Health Care System, Manhasset, New York, USA

    • David E Bernstein
  4. Division of Hepatology and Sandra Atlas Bass Center for Liver Diseases, Northwell Health, Manhasset, New York, USA

    • David E Bernstein


  1. Search for Paul Y Kwo in:

  2. Search for Mitchell L Shiffman in:

  3. Search for David E Bernstein in:

Competing interests

Guarantors of the article: All three authors take equal responsibility for its content.

Specific author contributions: Each author contributed equally to the drafting of the manuscript.

Financial support: None.

Potential competing interests: David Bernstein: Research support: Abbvie, Gilead, Merck; Ad Boards/consulting: Abbvie, BMS, Gilead, Merck; Speakers Bureau: Abbive, Gilead, Merck. Paul Kwo: Grant Support: Abbvie, BMS, Gilead, Merck; Advisory Board: Abbott, Abbvie, BMS, CVS, Gilead, Merck, Quest. Mitchell Shiffman: Grant support: AbbVie, Bristol Myers-Squibb, Conatus, CymaBay, Exalenz, Galectin, Genfit, Gilead, Intercept, Immuron, Merck, NGMBio, Novartis, Shire; Advisory meetings: AbbVie, Bristol Myers-Squibb, Gilead, Intercept, Merck; Speaker: AbbVie, Bayer, Bristol Myers-Squibb, Daiichi Sankyo, Gilead, Intercept, Merck; Consulting: Optum Rx.

Corresponding author

Correspondence to Paul Y Kwo.